Novel anti-viral therapeutic

Patent metadata

Field	Value
Publication number	US-2016243149-A1
Application number	US-201615073037-A
Country	US
Kind code	A1
Filing date	Mar 17, 2016
Priority date	Apr 20, 2012
Publication date	Aug 25, 2016
Grant date	—

Abstract

Anti-viral therapeutics for use in viral targets having VPg unlinkase activity, including the broad class of picornaviruses, and therapeutic methods directed at suppression of such activity are provided. Such anti-viral therapies for use against human rhinovirus, for example, are particularly desirable as they would lessen both the severity and duration of upper respiratory distress in both normal and asthmatic individuals. Assays and purification protocols for detecting and purifying VPg unlinkase are also provided.

First claim

What is claimed is:

1 . A method of treatment or inhibiting picornavirus replication, said method comprising:
administering a therapeutically effective amount of an inhibitor compound to a human host infected with a picornavirus, said step of administering comprising one of intranasal, oral or intravenous administration of the inhibitor compound to the human host; and wherein the inhibitor compound inhibits the release of picornavirus viral protein genome-linked (VPg) by tyrosyl-DNA phosphodiesterase 2 (TDP2).

2 . The method of claim 1 further comprising:
diagnosing or identifying a human host with a picornavirus infection prior to administering.

3 . The method of claim 1 , wherein the picornavirus comprises of human rhinovirus, poliovirus, coxsackievirus, and enterovirus.

4 . The method of claim 1 , wherein the inhibitor compound is 5′-p-fluorosulfonylbenzoyladenosine (5′FSBA).

5 . A method of treatment or inhibiting picornavirus replication, said method comprising:
administering a therapeutically effective amount of a synthetic nucleic acid polymer inhibitor to a human host infected with a picornavirus, said step of administering comprising one of intranasal, oral or intravenous administration of the inhibitor; wherein the synthetic nucleic acid compound is selected from the group consisting of a single-stranded deoxyribonucleic acid (ssDNA) polymer and a single-stranded ribonucleic acid (ssRNA) polymer; and wherein the inhibitor inhibits the release of picornavirus VPg by tyrosyl-DNA phosphodiesterase 2 (TDP2).

6 . The method of claim 5 further comprising:
diagnosing or identifying a human host with a picornavirus infection prior to administering.

7 . The method of claim 5 , wherein the synthetic nucleic acid polymer has a 5′-tyrosyl bond.

8 . The method of claim 7 , wherein the 5′-tyrosyl bond is hydrolysable.

9 . The method of claim 5 , wherein the synthetic nucleic acid polymer is bonded to a tyrosine amino acid by a covalent bond.

10 . The method of claim 9 , wherein the covalent bond is a 5′-tyrosyl bond.

11 . The method of claim 5 , wherein the synthetic nucleic acid polymer is bonded to a peptide chain by a covalent bond.

12 . The method of claim 11 , wherein the covalent bond is a 5′-tyrosyl bond.

13 . The method of claim 5 , wherein the picornavirus comprises of human rhinovirus, poliovirus, coxsackievirus, and enterovirus.

14 . An assay for monitoring the release of viral protein, genome-linked (VPg) from picornavirus genomic RNA generally comprising:
generating a picornavirus genomic RNA containing an 35 S-labeled VPg; incubating the 35 S-labeled VPg with an extraction comprising tyrosyl-DNA phosphodiesterase 2 (TDP2); running the 35 S-labeled VPg in a gel electrophoresis apparatus; and monitoring the cleavage of the labeled VPg from the picornavirus genomic RNA.

15 . The assay of claim 14 , wherein the step of generating comprises:
supplying a picornavirus-infected cell with a [ 35 S]methionine marker; and extracting the labeled virion RNA from the virus-infected cells.

16 . The assay of claim 15 , wherein the extracting comprises sucrose gradient fractionation.

17 . The assay of claim 14 further comprising:
digesting the 35 S-labeled VPg with RNAse T1.

18 . A tyrosyl-DNA phosphodiesterase 2 (TDP2) purification protocol comprising:
providing a cell homogenate that contains TDP2; and sequentially fractionating the supernatant by heparin Sepharose, ssDNA-cellulose, anion exchange, size exclusion, and cation exchange chromatography to produce a substantially homogeneous enzyme preparation.

19 . The purification protocol of claim 18 , further comprising:
concentrating the TDP2 by centrifugation.

20 . The purification protocol of claim 19 , wherein the TDP2 concentrate is in a supernatant.

Assignees

• Univ California

Inventors

• Semler Bert L
• Virgen-Slane Richard
• Rozovics Janet M
• Gershon Paul D

Classifications

• A61K31/00

  Medicinal preparations containing organic active ingredients · CPC title

• C12N9/16

  acting on ester bonds (3.1) · CPC title

• G01N27/44791

  Microapparatus (sample containers with integrated microfluidic structures B01L3/5027) · CPC title

• A61K31/7076 Primary

  containing purines, e.g. adenosine, adenylic acid · CPC title

• G01N27/4476

  of the density gradient type · CPC title